Role of matrix metalloproteinases in asthma

被引:123
作者
Kelly, EA [1 ]
Jarjour, NN [1 ]
机构
[1] Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Dept Med, Madison, WI 53972 USA
关键词
D O I
10.1097/00063198-200301000-00005
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Airway inflammation and remodeling are key features of asthma. Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs) are thought to contribute to the pathogenesis of asthma via their influence on the function and migration of inflammatory cells as well as matrix deposition and degradation. TIMPs bind MMPs in a 1:1 fashion. Thus, an increase in the molar ratio of MMP/TIMP may favor tissue injury, while the reverse could be associated with increased fibrosis. MMP-9 is the predominant MMP in asthma, and its expression is enhanced when patients have spontaneous exacerbations or in response to local instillation of allergen in the airway. As acute inflammation resolves, MMP-9 levels return toward normal. Interestingly, corticosteroids downregulate MMP and enhance TIMPs. Even though it is clear that enhanced airway inflammation in asthma is associated with increased expression of MMPs, whether specific inhibitors of MMP could reduce airway injury and facilitate orderly healing in asthma is still unknown. (C) 2003 Lippincott Williams Wilkins, Inc.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 39 条
  • [1] Serum matrix metalloproteinase-9:: Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma
    Bossé, M
    Chakir, J
    Rouabhia, M
    Boulet, LP
    Audette, M
    Laviolette, M
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (02) : 596 - 602
  • [2] Tissue inhibitors of metalloproteinases: evolution, structure and function
    Brew, K
    Dinakarpandian, D
    Nagase, H
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2): : 267 - 283
  • [3] Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics
    Cataldo, D
    Munaut, C
    Noel, A
    Frankenne, F
    Bartsch, P
    Foidart, JM
    Louis, R
    [J]. ALLERGY, 2001, 56 (02) : 145 - 151
  • [4] Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency
    Corry, DB
    Rishi, K
    Kanellis, J
    Kiss, A
    Song, LZ
    Xu, J
    Feng, LL
    Werb, Z
    Kheradmand, F
    [J]. NATURE IMMUNOLOGY, 2002, 3 (04) : 347 - 353
  • [5] Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
    Coussens, LM
    Fingleton, B
    Matrisian, LM
    [J]. SCIENCE, 2002, 295 (5564) : 2387 - 2392
  • [6] Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma
    Dahlen, B
    Shute, J
    Howarth, P
    [J]. THORAX, 1999, 54 (07) : 590 - 596
  • [7] EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131
  • [8] Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability
    Fowlkes, JL
    Winkler, MK
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (03) : 277 - 287
  • [9] Lung elastic recoil in acute and chronic asthma
    Gelb, AF
    Zamel, N
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2002, 8 (01) : 50 - 53
  • [10] Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards Type-2 in experimental pulmonary tuberculosis in Balb/c mice
    Hernandez-Pando, R
    Orozco, H
    Arriaga, K
    Pavön, L
    Rook, G
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2000, 81 (03) : 199 - 209